Skip to main content
. 2023 Jan 24;29(9):1719–1729. doi: 10.1158/1078-0432.CCR-22-2177

Figure 2.

Figure 2. High bTMB at baseline is associated with poor patient outcomes. A, Distribution of bTMB scores across 50 baseline patient samples sequenced by PredicineWES+. High bTMB scores were significantly associated with (B) lack of clinical benefit (CB) defined as progressive disease (PD) within 6 months and (C) the presence of ESR1 mutations at baseline (Wilcoxon test; FDR P = 0.016). D, Clinical classification of endocrine resistance per ESMO 2020 guidelines did not predict bTMB, although there were a greater number of patients with high bTMB in the endocrine resistant cohort (Kruskal–Wallis test). The association of high bTMB with significantly shorter PFS was observed using multiple cutoffs for bTMB including the median (E), third quartile (F), or bTMB scores of 10 mutations/megabase (G; log rank test). H, Within the endocrine resistant cohort, high bTMB scores were significantly associated with shorter PFS (log-rank test).

High bTMB at baseline is associated with poor patient outcomes. A, Distribution of bTMB scores across 50 baseline patient samples sequenced by PredicineWES+. High bTMB scores were significantly associated with (B) lack of clinical benefit (CB) defined as progressive disease (PD) within 6 months and (C) the presence of ESR1 mutations at baseline (Wilcoxon test; FDR P = 0.016). D, Clinical classification of endocrine resistance per ESMO 2020 guidelines did not predict bTMB, although there were a greater number of patients with high bTMB in the endocrine-resistant cohort (Kruskal–Wallis test). The association of high bTMB with significantly shorter PFS was observed using multiple cutoffs for bTMB including the median (E), third quartile (F), or bTMB scores of 10 mutations/megabase (G; log rank test). H, Within the endocrine-resistant cohort, high bTMB scores were significantly associated with shorter PFS (log-rank test).